Efficacy and safety of bimatoprost 0.03% in patients with elevated intraocular pressure:a comparison with latanoprost 0.005%

Objective To compare the efficacy and safety of bimatoprost and latanoprost in patients with primary open angle glaucoma and ocular hypertension. Methods Randomized,investigator-masked,parallel-group clinical trial.Patients(n=56)with primary open angle glaucoma or ocular hypertension were randomly assigned to receive bimatoprost 0.03% or latanoprost 0.005% topically once daily,in the evening,for 6 weeks.The primary endpoint was the reduction in IOP from baseline on day 42.Secondary outcome measures included eye examinations and safety parameters. Results Bimatoprost and latanoprost significantly lowered IOP from baseline( P 0.001)at each time point.Mean IOP reduction ranged from 5.92mmHg to 9.18mmHg(26.3%～36.1%)with bimatoprost and from 7.25mmHg to 9.85mmHg(31.3%～38.9%)with latanoprost( P 0.05)after 6 weeks medication.Both treatment regimens were safe and well tolerated,with no significant between group differences in reports of specific adverse events.The most common side effect was conjunctival hyperemia. Conclusions Both bimatoprost and latanoprost effectively lowered IOP and was safe and well tolerated in Chinese patients with primary open angle glaucoma or ocular hypertension.The between group differences were not statistically significant.